Content
Search
Navigation
Sitemap

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Late-stage clinical companies companies
Autolus Therapeutics
Beacon Therapeutics
all Clinical companies companies
Achilles Therapeutics
Anaveon
SwanBio Therapeutics
Freeline Therapeutics
Quell Therapeutics
all Pre-clinical companies companies
Resolution Therapeutics
Purespring Therapeutics
Clade Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics

14.11.23

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Clinical companies
Achilles Therapeutics

04.08.23

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Operating News
Clinical companies
Achilles Therapeutics

12.06.23

Achilles Therapeutics to Present at Upcoming Conferences 2023

Clinical companies
Achilles Therapeutics

10.05.23

Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

Clinical companies
Achilles Therapeutics

10.05.23

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Clinical companies
Achilles Therapeutics

25.04.23

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

Operating News
Clinical companies
Achilles Therapeutics

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

Copyright © Syncona 2023
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern slavery statement

Syncona Limited is registered in Guernsey no. 55514, registered office Frances House, PO Box 273, Sir William Place, St. Peter Port, Guernsey, GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

threethirty.studio

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

GBX 121.00

Change: -3.40 (-2.73%)

Search

Search